Clinical, molecular, and immune correlates of Immunotherapy Response Score in advanced urothelial carcinoma patients under atezolizumab monotherapy: Analysis of the phase 2 IMvigor210 trial medrxiv.org/content/10.1101/20

Sign in to participate in the conversation
CleverLibre Social

CleverLibre Social is an inclusive social instance for open discussion, learning, and community.
All cultures welcome.
Hate speech and harassment strictly forbidden.